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Introduction 
TIncidence of Hepatocellular Carcinoma (HCC) has been on the rise 
in the United States lately attributed to an increase of chronic hepatitis 
B and C [1]. Furthermore, obesity and diabetes may be additional risk 
factors to an increased rate of HCC [2]. American Association for the 
Study of Liver Disease (AASLD) recommends imaging studies for 
surveillance for patients at risk for HCC [3]. The Ultrasound (US) is 
used as the first line modality for HCC screening, followed by dynamic 
Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). 
Imaging modalities for clinical diagnosis have changed medical practice 
in HCC surveillance in recent years mitigating the risks associated with 
liver biopsy. However, there are concerns for the cost and excessive 
radiation exposure using imaging study for surveillance. Therefore, 
the imaging techniques are usually applied annually or 6 monthly for 
screening. However, doubling time of liver cancer is approximately 
6 months on average [4]. To detect HCC in treatable stage, AASLD 
recommends 3-6 months surveillance interval [3]. Also, National 
Comprehensive Cancer Network (NCCN) Clinical Practice Guideline 
on hepatobiliary cancer made similar recommendation [5]. NCCN 
clinical practice guideline also recommends Alpha-Fetoprotein (AFP) 
combined with imaging modalities. In general, the serum and imaging 
biomarkers are specific with high positive predictive value (PPV), but 
less sensitive, therefore having low Negative Predictive Value (NPV) 
for HCC surveillance [6,7].
Recently two novel serum biomarkers for HCC risk assessment, 
the Lectin-reactive Alpha-Fetoprotein (AFP-L3) and Des-Gamma-
Carboxy Prothrombin (DCP) have been introduced into clinical 
practice. AFP-L3 is a glycosylation variant of AFP [8]. DCP is 
abnormal coagulation protein produced in the liver and a precursor of 
thrombin in the coagulation cascade [9]. These serum biomarkers are 
highly specific for HCC [10-12]. Recently, the second generation of the 
automated assays has been developed. This assay utilizes microfluidic 
chip-based assay technologies. Highly sensitive serum biomarkers are 
in great need for surveillance of HCC combined with high negative 
predictive value. Thus, only patients with positive results would need 
imaging study. Toyoda et al. showed that the high sensitivity of AFP-L3 
is especially useful for patients with AFP <20 ng/mL with a lower cut-off 
at 5% [13]. Hanaoka et al. demonstrated that combination of AFP-L3 
and DCP further enhanced the assay sensitivity [14]. In 2007, Carr et 
al. examined these markers in 98 patients with unresectable HCC in the 
U.S. using Liquid Phase Binding Immunoassay (LiBASys) and reported 
that the combination of AFP, AFP-L3% and DCP was superior to 
individual marker alone in the diagnosis of HCC [15]. They also found 
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Abstract
Background and aims: Early detection of Hepatocellular Carcinoma (HCC) is crucial for effective management. 
Incidence of HCC has increased in the United States largely attributed to hepatitis B and C virus. Lens culinaris 
agglutinin-reactive Alpha-Fetoprotein (AFP-L3) and Des-Gamma-Carboxy Prothrombin (DCP) are being recognized 
specific biomarkers for HCC. 
Methods: We measured AFP-L3 and DCP in serial serum specimens of a cohort of chronic hepatitis patients 
on HCC surveillance and compared these markers to abdominal imaging. Among fifty patients who developed HCC 
during surveillance, 30 were included in the study with available sera 1-2 years before, at diagnosis and post ablation 
of HCC. For controls, three consecutive annual sera were examined from 106 chronic hepatitis patients without 
HCC during surveillance for 5-10 years. The µTASWako i30 auto analyzer was used for the assay that utilizes the 
microfluidics chip based assay platform. It can fractionate AFP-L3 glycoform and calculates AFP-L3% if AFP level 
is ≥ 0.6 ng/mL. 
Results: Combination of AFP, AFP-L3 and DCP showed high sensitivity of 83% in all patients and 75% in 
patients with AFP<20 ng/mL. AFP-L3 and DCP assays were useful in patients with low levels of AFP (<20 ng/mL) 
and could detect significant AFP-L3% elevation in some patients more than one year before the diagnosis of HCC. 
Furthermore, AFP-L3 predicted recurrence of HCC. 
Conclusions: This is the first study in the U.S. patients using the µTASWako i30 analyzer to test these HCC 
biomarkers. Our results suggest that combinations of these biomarkers are highly useful for early detection of HCC.
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that AFP-L3% was significantly related to portal vain invasion and 
patient outcome suggesting AFP-L3% as a potential prognostic marker. 
In this study, utilizing the newly developed microfluidic chip 
platform (by Wako), we measured these biomarkers in the serum 
samples collected prospectively from 1999 to 2011 from a cohort of 
patients with chronic hepatitis without HCC, some of whom developed 
HCC during the follow-up period. This patient cohort has been on 
long term surveillance at the Liver Disease Prevention Center, Division 
of Gastroenterology and Hepatology, Thomas Jefferson University 
Hospital with 3-6 monthly AFP and biannual imaging. The majority 
had chronic hepatitis B with or without cirrhosis. We investigated the 
usefulness of these biomarkers for surveillance for HCC. Most subjects 
have had low AFP level <20 ng/mL. This is the first study in the U.S. 
using the novel and highly sensitive biomarkers assay on µTASWako 
i30 analyzer for patients who are on HCC surveillance.
Patients and Methods
Patients
Included in the study were patients most of whom had Chronic 
Hepatitis B (CHB) or Chronic Hepatitis C (CHC). The majority were 
Asian Americans. They were on HCC surveillance with 6 monthly 
AFP and 6 monthly abdominal imaging for minimum 5 years and 
longer between February 1999 and August 2011. Selection of HCC 
patients and controls for the study was based on the availability of 
the specimens. To be eligible for the study, HCC patients had to have 
sera obtained; 1-2 years before HCC diagnosis, at diagnosis and post-
treatment follow up period. For controls with chronic hepatitis who 
did not develop HCC during surveillance, three consecutive annual 
serum samples were required. All had to have 6 monthly or annual 
imaging including ultrasound. Based on the criteria, 30 HCC patients 
and 106 controls were selected. HCC patients were diagnosed initially 
by imaging studies including US, CT or MRI. For the final diagnosis 
of HCC, the dynamic MRI was used as defined by AASLD guideline 
[16-18] and by our institution [19] that shows a mass demonstrating 
low to intermediate T1 signal on pre-contrast images, homogeneous, 
heterogeneous, or ring enhancement during the hepatic arterial phase 
and/or moderate hyperintensity on intermediate T2-weighted fat 
suppressed spin-echo images with washout relative to surrounding liver 
parenchyma on delayed post contrast images. To ensure that controls 
did not have HCC, they were followed for 2-3 years longer after the 
last serum sampling. Treatment for HCC was decided according to the 
treatment guidelines for HCC in the USA [3,20-22]. 
The study protocol was approved by the Institutional Review 
Board at Thomas Jefferson University and was in compliance with the 
declaration of Helsinki.
Measurements of AFP, AFP-L3 and DCP
AFP, AFP-L3 and DCP were measured in the serum sample 
obtained 1-2 years prior to the diagnosis of HCC, at the time of 
diagnosis and during the follow up period after tumor ablation (for 
HCC group) and from serum samples obtained annually during which 
time the absence of HCC was confirmed (for the control group). 
AFP, AFP-L3 and DCP were measured using a microchip capillary 
electrophoresis and liquid-phase binding assay on a µTASWako i30 
auto analyzer (Wako Diagnostics, Wako Life Sciences, Inc. Mountain 
View, California, USA). [23]. The measurement range was 0.3-1000 
ng⁄mL for AFP and 0.1-950 ng/mL for DCP. The percentage of AFP-L3 
on the i30 analyzer can be calculated when AFP is over 0.6 ng⁄mL 
compared to 10 ng/mL on the previous platform, LIBASys. The total 
precisions for nine concentration levels of the three biomarkers were 
less than 8% coefficient of variations in 21 days of evaluation. This new 
assay platform has enabled the accurate measurement of AFP-L3 with 
a high sensitivity and at low AFP concentrations. All processes were 
preformed automatically and followed the manufacture’s instruction. 
Statistical analyses
Receiver Operation Characteristic (ROC) analysis was used to 
evaluate the optimum cut-off values for AFP, AFP-L3 and DCP assays 
on µTASWako i30. To evaluate the diagnostic value of AFP-L3 and 
DCP, sensitivity, specificity Positive Predictive Value (PPV) and 
Negative Predictive Value (NPV) were estimated by using the cut-offs 
which are approved by FDA and currently used in medical practice 
in the USA. In addition, the optimum cut-offs were calculated. The 
sensitivity, specificity, PPV and NPV for patients who have low 
concentration of AFP (<20 ng/mL) were calculated. All analyses were 
performed using JMP5 statistical software (SAS Institute, Cary, NC, 
USA).
Results
Demographics of the study population
The study cohort consisted of 136 chronic hepatitis patients with 
or without cirrhosis who have been under surveillance for HCC from 
1999 to 2011. 
Of the 136, 30 patients developed HCC during surveillance period 
and 106 did not. 
Detailed characteristics of HCC patients and controls are shown 
in Table 1. In both Groups there were more men than women. HCC 
patients were 10 years older in average than the controls. The majority 
had chronic hepatitis B.
As shown in Table 2, of the 30 HCC patients, 26 had HBV, 3 with 
HCV and one without viral infection. Details of the underlying liver 
diseases including liver cirrhosis and the HBeAg status are given in the 
table. 
Characteristics Patients with HCC
(n=30)
Patients without HCC
(n=106)
Gender (%)
Male/Female 25 (83) / 5 (17) 69 (65) / 37 (35)
Age
Mean ± SD 59.1 ± 10.3 48.4 ± 10.8
Infection hepatitis virus 
(%) HBV/HCV/HBV+HCV/
none
26 (87)/3 (10)/0 (0)/1 (3) 105 (99)/0 (0)/0 (0)/1 (1)
Chronic Hepatitis/Liver 
cirrhosis (%)
N/A 87 (82) / 19 (18)
Tumor size   
≤ 2 cm 14 N/A
>2 cm and ≤ 3 cm 6 N/A
>3 cm and ≤ 5 cm 8 N/A
>5 cm 2 N/A
Number   
 Single 23 N/A
Multiple 7 N/A
Table 1: Patient Characteristics.
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Clinical performance characteristics
 Table 3 shows the sensitivity (true-positive rate), specificity 
(true-negative rate), Positive Predictive Value (PPV) and Negative 
Predictive Value (NPV) of the AFP, AFP-L3 and DCP using current 
recommended cut-offs for risk assessment in HCC surveillance from 
the manufacturers. The sensitivity of AFP, AFP-L3 and DCP is 13, 
47, 13% respectively based on the cut-off value for AFP, AFP-L3 and 
DCP as 200 ng/mL, 10% and 7.5 ng/mL. It is noted that all three serum 
biomarkers demonstrated very high but comparable clinical specificity 
of greater than 98% with AFP-L3 having the highest or more than 
double the sensitivity of the other two biomarkers. This suggests that 
when used individually, the HCC biomarkers could be effective for 
rule in diagnosis since the PPV is favorable. However it may not be as 
effective for screening of patients at high risk of HCC. 
Receiver Operating Characteristics (ROC) curve: The clinical 
performance characteristics of the serum biomarkers are compared in 
ROC analysis. Among the three HCC serum biomarkers, AFP has a 
slightly greater ROC of 0.836 compared to AFP-L3 of 0.820 and DCP 
of 0.728. The optimal cutoffs for AFP, AFP-L3 and DCP are 5.6 ng/mL, 
4.5% and 0.57 ng/mL, respectively, and are lower than those currently 
applied for clinical diagnosis.
Optimal cut-off threshold for HCC surveillance: The current 
manufacturer’s recommended cut-off value may not be suited for 
risk assessment in surveillance for different subgroup of chronic viral 
hepatitis patients. In our study group, most patients with chronic 
hepatitis and cirrhosis had HBV infection. From this data set, we 
calculated the optimal cut-off thresholds for the AFP-L3 and DCP for 
our study subjects. 
Based on the ROC analysis of this data set, when optimal cut-offs 
of 4.5% for AFP-L3 and 0.57 ng/mL for DCP were used, the sensitivity 
of the AFP-L3 and DCP becomes 70% and 53.3%, respectively (Table 
4). Therefore, clinical sensitivities of the AFP-L3 and DCP improve 
significantly with only minor decrease in the specificity. Therefore, 
these cut-offs (AFP-L3 4.5%, DCP 0.57 ng/ml) would be more useful 
for risk assessment in HCC surveillance. 
Combined use of the HCC serum biomarkers: The clinical 
sensitivities of the combined AFP-L3 and DCP assays are shown in 
Table 4. Notably, the sensitivity is increased to 83.3% with greater than 
90% specificity for all the samples measured in the study. For patients 
with AFP <20 ng/mL (n=16 HCC; and n=102 CH controls), AFP-L3 
has sensitivity of 50% and DCP 48.3%. In combination, AFP-L3 and 
DCP showed 75% of sensitivity and over 94% specificity. The ROC 
of different combinations of the HCC serum biomarkers shows that 
combination of AFP-L3 and DCP improve the AUC with 0.900 
compared to AFP and AFP-L3 (0.846), AFP and DCP (0.874) and AFP, 
AFP-L3 and DCP (0.874).
Changes of AFP, AFP-L3, and DCP value in patient’s overtime: 
High sensitivity indicated high risk of HCC development among the 
patients with chronic hepatitis and cirrhosis. Since the assays are 
more sensitive to the underlying pathological changes of HCC in the 
background of cirrhosis, it was important that prospectively collected 
serum specimens were available long before the HCC confirmation by 
MRI. Of the 30 HCC patients, 7 patients had multiple serum samples 
before HCC diagnosis. As shown in (Figure 1), 6 out of 7 patients 
(86%) with multiple specimens collected before the HCC diagnosis 
showed elevation of AFP-L3 level (≥ 5%) of a lead time of more than 1 
year before diagnosis of HCC by MRI.
Predicting HCC recurrence: Of the 30 HCC patients, 8 patients 
had recurrent tumor after the initial successful ablation and had 
the markers examined in the serum collected after tumor ablation. 
Measurements for AFP-L3 and DCP are summarized in Table 5. Six of 
the 8 patients showed elevation of either AFP-L3 level of ≥ 5% or DCP 
of ≥ 0.57 ng/mL after treatment that predicted recurrence. 
Discussion
Early detection of HCC at the treatable stage is imperative for 
effective HCC management. Sherman suggests that HCC <3 cm in 
diameter is critical for achieving successful treatment [6]. AFP, albeit 
having been used for HCC diagnosis in clinical settings, is a non-
specific biomarker of HCC since it often increases in hepatic necro 
inflammation [24]. It is a poor indicator of HCC with low levels of AFP 
(<20 ng/mL). 
In HCC surveillance, highly sensitive serum biomarkers play 
important roles because of their high negative predictive values that 
can minimize the false negative results of less sensitive assays. Only 
patients with seropositive results may need imaging confirmation. 
While the imaging modalities provide confirmative diagnosis, they are 
expensive with limited access in physicians’ clinic for surveillance.
In this study, we measured serial serum specimens from a cohort 
of 136 patients with chronic viral hepatitis and cirrhosis. These patients 
have been closely monitored for HCC development with 3-6 monthly 
 patients with HCC 
no=30
Patients without HCC 
no=106
Underlying liver disease
Chronic hepatitis (%) 10 (33) 87 (82)
Cirrhosis (%) 20 (66) 19 (18)
Compensated (%) 16 (53)  13(12.3)
Decompensated (%) 4 (13)  6 (5.6)
HBsAg (+) 26 (87) 105 (99)
HBeAg (+) 5 (17) 32 (30)
HBeAg (-) 21 (70) 73 (69)
HCV 3 (10) 0 (0)
None 1 (3) 1 (1)
Table 2: Patients’ liver disease status and viral markersa.
 Cut-off Sensitivity 
(%)
Specificity 
(%)
PPV
(%)
NPV
(%)
AFP 200 ng/mL 13 98 67 80
AFP-L3 10% 47 98 88 87
DCP 7.5 ng/mL 13 99 80 80
Table 3: Sensitivity and Specificity of AFP, AFP-L3 and DCP in patients with and 
without HCC using the current cut-off values.
Cut-off Sensitivity 
(%)
Specificity 
(%)
PPV
(%)
NPV
(%)
All samples      
   AFP-L3 4.5% 70.0 92.5 72.4 91.6
   DCP 0.57 53.3 98.1 88.9 88.1
   AFP-L3 + DCP  83.3 91.3 73.5 95.1
AFP <20 ng/mL  (HCC: n=16, Control: n=102) 
AFP-L3 4.5% 50.0 94.1 57.1 92.3
   DCP 0.57 43.8 100.0 100.0 91.9
   AFP-L3 + DCP  75.0 94.1 66.7 96.0
The clinical sensitivities would be significantly improved by using the optimal cut-
offs derived from this study data set and further increased by combining all three 
biomarkers. 
Table 4: Optimal Cut-off Values Derived from ROC Analysis for the current study.
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AFP and 6 monthly imaging for HCC for a minimum of 5-10 years. 
Thirty patients who developed HCC during surveillance (26/30 with 
had HBV) and 106 controls (105/106 with HBV) were enrolled. Our 
study of HCC biomarkers demonstrated extremely high specificity. 
Individual HCC biomarker’s sensitivity using current recommended 
cut-off level is relatively low from 13% to 47%. Among these, the 
sensitivity of AFP-L3 is the highest. In addition, HCC patients detected 
by the individual HCC biomarkers do not overlap suggesting the 
heterogeneities of HCC. The relative low sensitivity of individual 
biomarkers is to be expected if used independently because each 
subtype of the HCC may be defined by different biomarkers. 
In the past study using the previous platform (LiBASys), DCP had 
highest sensitivity and were the most accurate tumor marker, and were 
suggested to be used for HCC surveillance [25]. However, AFP-L3 did 
not show adequate sensitivity to be considered a surveillance tool for 
HCC although it had high specificity.
In the current study, AFP-L3 on the µTASWako i30 had the 
highest sensitivity using lower cut-off (5%) compared to AFP and 
DCP [26]. In focusing on the patients with less than 20 ng/mL of AFP, 
AFP-L3 levels were significantly higher in HCC than in non-HCC and 
the sensitivity of AFP-L3 for HCC detection was more than 70% with 
cut-off of 5%. In addition of this study, the combination of AFP-L3 
and DCP improved the sensitivity reaching the level of close to 90% 
and showed significantly increased AUC even in patients with low AFP 
concentration.
The significant improvement of clinical sensitivity of the biomarkers 
observed in this study is largely due to the novel assay technologies 
that utilized microfluidics chip based assay platform. Compared to the 
older version assays performed on Liquid Phase Binding Immunoassay 
(LiBASys) platform, the current analyzer can fractionate AFP-L3 
glycoform and calculate the percentage of AFP-L3 at the AFP level of 
≥ 0.6 ng/mL, the amount which virtually cover the entire reportable 
range of AFP. Sherman et al reported that a large portion of patients 
(20-80%) with liver cancer would not have AFP >20 ng/mL depending 
on the size of HCC at diagnosis [27]. AFP has low sensitivity for 
surveillance at the current cut-off level that is designed for rule-in 
HCC diagnosis. Therefore, AFP has not been recommended for HCC 
surveillance by AASLD guideline [3]. Changing the cutoff threshold to 
lower range would improve sensitivity but decrease specificity thereby 
increasing false positivity. 
In our study, we demonstrated that AFP-L3 had higher sensitivity 
in all patients as well as in patients with AFP level less than 20 ng/
No. Sex Etiology AFP U% DCP HCC
/Non-HCC
Imaging Size of
tumor (cm)
Number of
tumor
1 M HBV 8.4 74.2 0.89 HCC MRI 3.5x2.4 1
2 F HBV 2419.3 9.6 0.26 HCC MRI 1.7x1.8 1
3 M HBV 3.1 10.7 0.24 Suspious MRI 0.7 1
4 M HBV 206.1 2.5 79.88 HCC MRI 1.2 1
5 M HBV 2.3 0.5 0.38 HCC MRI 1.6x1.4 1
6 M HBV 9.3 28.8 0.37 HCC MR1 3.0, 4.0 2
7 M HBV 3.8 0.5 0.10 HCC MRI 2.0 1
8 M HBV 4.3 7.0 0.11 Suspious MRI 2.0x1.8 1
In 5 among 8 patients with specimens after successful treatment, the AFP-L3 values were elevated before the recurrence (by MRI) in comparison to only 2 each for AFP 
and DCP (cut-offs for L3% 4.5 and for DCP 0.57). 
Table 5: AFP, AFP-L3, and DCP in Predicting HCC Recurrence.
 
(ng/mL)
AFP AFP-L3
-30            -24           -18           -12            -6              0
Month  before  diagnosis Month  before  diagnosis
-30           -24            -18           -12            -6              0
Month  before  diagnosis
-30           -24           -18            -12            -6              0
DCP
(ng/mL)(%)
The unit on x-axis is month, 0 indicates the time of HCC diagnosis; on y-axis for AFP is ng/mL; AFP-L3 is %; and DCP is ng/mL.  Six of the 7 patients with multiple 
serum specimens showing elevated AFP-L3 >5% one year prior to MRI confirmation, while only 2 with AFP >20 ng/mL and 1 with DCP >7.5 ng/mL (AFP-L3 superior 
to others). 
Figure 1: Change of AFP, AFP-L3 and DCP Value Overtime before HCC Diagnosis.
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mL-70% and 50%, respectively. The combination of AFP-L3 and 
DCP improved the sensitivities to 83% and 75%, respectively. The 
seropositive HCC biomarkers of high sensitivity could indicate the 
high risk for HCC. For surveillance, a fixed cut-off is less significant 
than the changes of HCC biomarkers overtime. The relatively 
low sensitivity of individual serum biomarker in this study is not 
unexpected since HCC is probably not a single disease entity but of 
a group of liver malignancies having subtypes with different clinical 
outcomes [28]. AFP, AFP-L3, and DCP may be representing different 
disease subtypes. In our study, we are able to confirm the distribution 
patterns of the biomarker expression as reported previously [29,30]. 
We also observed that not all three biomarkers are expressed in HCC 
patients at the same time. AFP-L3 has been also reported as a biomarker 
for aggressive HCC, while DCP is a marker of intra hepatic metastasis 
[8,31]. Patients with primary malignant hepatic tumors seropositive for 
AFP-L3 and low AFP concentrations present unique clinicopathologic 
features. These cancers are reported having a higher incidence of non-
HCC primary liver cancer derived from cholangiocytes. They also had 
a high frequency of poorly differentiated tumors and sarcomatous 
changes, and showed a poor prognosis [32]. Patient’s positive for 
AFP-L3 and negative for DCP demonstrated histopathologic features 
of more advanced HCC while those positive for DCP alone presented 
infiltrative and poorly differentiated HCC [33]. Okuda et al. found that 
a subgroup of Intrahepatic Cholangiocarcinoma (ICC) seropositive for 
AFP-L3, and patients with combined HCC and ICC have features more 
like HCC. They suggest that these liver cancers are different from the 
ICC which is seropositive for CA19-9 [34]. This supports that AFP-L3 
seropositive HCC is a subtype with aggressive behavior.
The limitation of our study is the small number of patients. While 
several hundreds of patients with chronic hepatitis B have been 
under surveillance for HCC only 136 met the eligibility criteria for 
the study. Nonetheless, the trending of these two HCC biomarkers 
even before MRI confirmation is encouraging and presents a testable 
hypothesis that these highly sensitive HCC biomarkers can be included 
as important markers for HCC surveillance. Due to the biological 
heterogeneity, some HCC was not detected by the 3 biomarkers. We 
expect this performance gap would be narrowed with additional new 
HCC serum biomarkers in the future. In this regard, Shen et al. reported 
that a new serum biomarker of Dickkopf-1 (DKK1) could complement 
AFP for patients with negative AFP [35]. Other new potential serum 
biomarkers have been reported as well [36,37].
Conclusions
Our study suggests that AFP-L3 and DCP are highly specific for 
HCC, and the clinical sensitivity can significantly improve if AFP, AFP 
L3 and DCP are used together for HCC surveillance. Serial testing 
would also greatly improve clinical sensitivity in surveillance of risk of 
HCC development. The highly sensitive AFP-L3 and DCP assays would 
be useful in patients with AFP in reference range <20 ng/mL and can 
detect significant AFP-L3% elevation in some HCC cases more than 
one year prior to confirmative HCC diagnosis. In addition, AFP-L3 
may be useful in predicting the recurrence of HCC after treatment. 
Combination of AFP-L3 and DCP and serial sampling for parallel 
testing can improve clinical sensitivity of the overall testing results 
while maintaining clinically acceptable high specificity.
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